GOLETA, Calif.–(BUSINESS WIRE)–Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company’s management will be participating in the 40th Annual J.P. Morgan Healthcare Conference.
Inogen’s President and CEO, Nabil Shabshab, is scheduled to present on Wednesday, January 12th, 2022 at 10:30 a.m. PT. Interested parties can access the live audio webcast from the News / Events section of the Investor Relations page on the Inogen website at www.inogen.com. A webcast replay will be available approximately one hour after the conclusion of the live presentation and will remain available for 90 days.
Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.
About Inogen
Inogen is a medical technology company offering innovative respiratory products for use in the homecare setting. Inogen primarily develops, manufactures and markets innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
For more information, please visit www.inogen.com.
Contacts
Investor and Media Contacts
Bryan Locke, Mike DeGraff, Gabriella Coffey
Inogen-SVC@sardverb.com
(312) 895-4700
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to…
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to…
Winter Park, Florida--(Newsfile Corp. - December 29, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a…
DaVita works with others in under-resourced communities to offer individualized health engagements, break down mistrust…
PONTE VEDRA, FL / ACCESS Newswire / December 29, 2025 / Every industry has its…
Contract Research Organization for the REGAL trial has informed the Company that 72 events have…